Treatment access

FDA approval of generic ARVs

We need the Patent Pool to work

FDA approval of generic ARVs

Global Fund adopts restructuring recommendations and close to 50% funding shortfall for next round of grants

Monitoring treatment in resource limited settings: results from PHPT-3 and Stratall ANRS12110/ESTER trials

DART: high rates of viral suppression after five years and a single CD4 test with a threshold of 250 cells/mm3 could reduce unnecessary switching

Lopinavir/r monotherapy used as second-line therapy in resource-limited settings

Gilead signs up for Medicines Patent Pool

FDA approval of generic ARVs

Patents and the pipeline: is access under threat?

An audit of HIV care provision for Immigration Removal Centre patients

FDA approval of generic ARVs

Global Fund reports rise in people on treatment

UK increases funding to the Global Fund

UK government development priorities and HIV

Update on the Patent Pool

TRIPS agreement flexibilities provide opportunities for improved access to ARVs

Driving a decade of change: HIV/AIDS, patents and access to medicines for all

FDA approval of generic ARVs

ART distribution and adherence support by community groups in Mozambique

Commentary: corruption by Global Fund grant implementers

Virological findings from the SARA trial ofboosted protease inhibitor monotherapy

Shortfall in funding for the Global Fund

FDA approval of generic ARVs

Europe! HANDS OFF OUR MEDICINE

DNP+ president uses 5ml of blood to meet Carla Bruni-Sarkozy

Medicines Patent Pool: first research funder announced

FDA approval of generic ARVs

IAS highlight funding shortfall crisis for Global Fund

The need for expanded access to experimental medicines for drug-resistant TB

Indian activists challenge proposed EU tradeagreements: Global access to Indian generic ARVs threatened

Russian HIV activists arrested in Red Square for protesting drug stock-outs

Chinese HIV positive activist Tian Xi to go on trial on trumped up charges

US waiting lists increase by over 300% in five months

Raltegravir approved inScotland

Atazanavir/r approved in Europefor children aged 6 to 18 years

FDA finally approves 4th generation HIV Ag/Ab test in the US

FDA approval of generic ARVs

FDA approval of generic ARVs

U.S. government leading backlash against AIDS funding

Evidence from six countries confirms fears of People Living With HIV/AIDS: treatment rationing is escalating

Launch of the 10th funding round and other outcomes from the Global Fund

FDA approval of generic ARVs

Waiting lists grow in the US

South African antiretroviral treatment guidelines (2010)

Tenofovir registered in Russia

MSF criticise Abbott over new ritonavir formulation

FDA approval of generic ARVs

UNITAID decision to fund ‘patent pool’ to boost access to new medicines

PEPFAR launches five-year strategy

Global Fund approves US$2.4 billion in new grants

AIDS and mortality in South Africa

Punishing success in tackling AIDS: funders retreat could wipe out health gains in HIV affected countries

FDA approval of generic ARVs

Five-year survival rates of 87% without routine CD4 or laboratory monitoring in DART study demonstrate an important model for ARV access programmes

Access to HIV treatment for UK prisoners

Lost benefit of ARVs in South Africa

FDA approval of generic ARVs

Brazil rejects Gilead patent on tenofovir

PEPFAR bill may lift US HIV travel and residency ban

Atripla to be licensed in Latin America and the Asia-Pacific region

FDA approval of generic ARVs

PEPFAR funding bill authorised by the US Senate

FDA approval of generic ARVs

Access to generic efavirenz in South Africa: MSD agrees to grant licenses on reasonable terms

Post navigation